3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
42
Carcinoma, Non-Small-Cell Lung
18
Neoplasms
15
Neoplasm Metastasis
14
Carcinoma, Renal Cell
10
Carcinoma, Hepatocellular
8
Ovarian Neoplasms
6
Colorectal Neoplasms
6
Uveal Melanoma
5
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Mesothelioma
5
Diabetes Mellitus, Insulin-Dependent, 12
5
Carcinoma, Transitional Cell
5
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Lung Neoplasms
4
Carcinoma, Merkel Cell
4
Advanced Cancer
4
Uterine Cervical Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Liver Neoplasms
3
Hodgkin Disease
3
Head and Neck Neoplasms
3
Carcinoma
3
Interventions
Gemcitabine
3
Capecitabine
3
tivozanib
2
pembrolizumab
2
Oxaliplatin
2
Cisplatin
2
trametinib
1
tislelizumab
1
spartalizumab
1
silmitasertib
1
pertuzumab
1
olutasidenib
1
devimistat
1
atezolizumab
1
Sorafenib
1
Ritonavir
1
Pemetrexed
1
Nivolumab
1
Itraconazole
1
Ipilimumab
1
Epirubicin
1
Carboplatin
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Bile Duct Neoplasms
×
Ipilimumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts